Poseida Therapeutics (NASDAQ:PSTX) Reaches New 52-Week High – Should You Buy?

Poseida Therapeutics, Inc. (NASDAQ:PSTX) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $9.62 and last traded at $9.62, with a volume of 238 shares. The stock had previously closed at $9.50.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PSTX shares. HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. BTIG Research reiterated a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Cantor Fitzgerald lowered shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 26th. Finally, Piper Sandler cut shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price objective for the company. in a research note on Monday, December 2nd. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $9.50.

Poseida Therapeutics Trading Up 0.1 %

The firm’s 50 day simple moving average is $4.84 and its 200-day simple moving average is $3.64. The company has a market capitalization of $929.83 million, a PE ratio of -15.08 and a beta of 1.64. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68.

Insider Buying and Selling

In other news, Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total transaction of $283,800.00. Following the transaction, the chairman now directly owns 651,291 shares of the company’s stock, valued at approximately $6,161,212.86. The trade was a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Poseida Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of Poseida Therapeutics during the 2nd quarter valued at approximately $31,000. Principal Financial Group Inc. acquired a new position in Poseida Therapeutics during the 2nd quarter valued at about $35,000. Rothschild Investment LLC bought a new position in Poseida Therapeutics in the 2nd quarter worth about $35,000. Virtu Financial LLC acquired a new position in shares of Poseida Therapeutics during the third quarter worth approximately $37,000. Finally, Intech Investment Management LLC bought a new position in Poseida Therapeutics in the 3rd quarter worth approximately $46,000. Hedge funds and other institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.